News
WASHINGTON, April 11, 2024 (GLOBE NEWSWIRE) -- Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic ...
Investigator-Sponsored Oral Presentation Vosoritide Increases Growth Velocity in Hypochondroplasia: Phase 2 Trial Results Oral Session: O03 Thursday, March 14, 2024, 1:30 – 3 p.m. ET About VOXZOGO ...
Vosoritide Increases Growth Velocity in Hypochondroplasia: Phase 2 Trial Results Oral Session: O03 Thursday, March 14, 2024, 1:30 – 3 p.m. ET About VOXZOGO In children with achondroplasia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback